Please login to the form below

Not currently logged in
Email:
Password:

Excellence in Rare Diseases and Orphan Drugs

Sponsored by

Back to Results


Finalist

Advancing ILD Research (AIR) Educational Series 2016/2017

by Roche with support from CMC


Summary of work

Idiopathic pulmonary fibrosis (IPF) is a rare and ultimately fatal lung disease characterised by a progressive and irreversible decline in lung function. IPF has a worse prognosis than many cancers, with a life expectancy of only 2–5 years from diagnosis if left untreated.

It can take a long time to reach an accurate diagnosis of IPF as various respiratory and non-respiratory diseases present with similar symptom profiles, and patients may be seen by non-specialists who do not recognise IPF or the need for a multidisciplinary approach that can aid earlier diagnosis.

The Advancing ILD Research (AIR) educational series was convened to successfully achieve the following:

  • Increase recognition and effective management of IPF and other interstitial lung diseases (ILDs)
  • Gain insight into key issues faced by clinicians in their daily practice
  • Educate on presenting history, symptoms, radiology and pulmonary function testing
  • Debate how best to support patients and carers living with IPF in dealing with the challenges a diagnosis can bring.

“It is unique in the world that for a rare disease such as IPF this kind of high level, dedicated symposium is possible…….it creates room to breathe for our patients” Professor Wim Wuyts, AIR Scientific Committee.

Judges' comments

The judges liked the patient involvement in the Roche and CMC entry. They had a broad reach to HCPs and a strong involvement with patient groups.



Highly commended


Highly commended

Infantile Onset Pompe Disease Schools Pack - by Sanofi Genzyme with support from Aurora Healthcare Communications


Finalists